Interleukin-13 immune gene therapy prevents CNS inflammation and demyelination via alternative activation of microglia and macrophages

Glia. 2016 Dec;64(12):2181-2200. doi: 10.1002/glia.23053. Epub 2016 Sep 29.

Abstract

Detrimental inflammatory responses in the central nervous system are a hallmark of various brain injuries and diseases. With this study we provide evidence that lentiviral vector-mediated expression of the immune-modulating cytokine interleukin 13 (IL-13) induces an alternative activation program in both microglia and macrophages conferring protection against severe oligodendrocyte loss and demyelination in the cuprizone mouse model for multiple sclerosis (MS). First, IL-13 mediated modulation of cuprizone induced lesions was monitored using T2 -weighted magnetic resonance imaging and magnetization transfer imaging, and further correlated with quantitative histological analyses for inflammatory cell influx, oligodendrocyte death, and demyelination. Second, following IL-13 immune gene therapy in cuprizone-treated eGFP+ bone marrow chimeric mice, we provide evidence that IL-13 directs the polarization of both brain-resident microglia and infiltrating macrophages towards an alternatively activated phenotype, thereby promoting the conversion of a pro-inflammatory environment toward an anti-inflammatory environment, as further evidenced by gene expression analyses. Finally, we show that IL-13 immune gene therapy is also able to limit lesion severity in a pre-existing inflammatory environment. In conclusion, these results highlight the potential of IL-13 to modulate microglia/macrophage responses and to improve disease outcome in a mouse model for MS. GLIA 2016;64:2181-2200.

Keywords: demyelination; magnetic resonance imaging; multiple sclerosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigens, Differentiation / metabolism
  • Bone Marrow Transplantation
  • Cuprizone / toxicity
  • Cytokines / genetics
  • Cytokines / metabolism
  • Demyelinating Diseases / chemically induced
  • Demyelinating Diseases / diagnostic imaging
  • Demyelinating Diseases / therapy*
  • Disease Models, Animal
  • Encephalitis / chemically induced
  • Encephalitis / diagnostic imaging
  • Encephalitis / therapy*
  • Genetic Therapy / methods*
  • Green Fluorescent Proteins / genetics
  • Green Fluorescent Proteins / metabolism
  • Interleukin-13* / genetics
  • Interleukin-13* / metabolism
  • Interleukin-13* / therapeutic use
  • Macrophages / drug effects*
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Microglia / drug effects*
  • Monoamine Oxidase Inhibitors / toxicity
  • Myelin Proteins / metabolism
  • Nerve Tissue Proteins / genetics
  • Nerve Tissue Proteins / metabolism
  • Transduction, Genetic

Substances

  • Antigens, Differentiation
  • Cytokines
  • Interleukin-13
  • Monoamine Oxidase Inhibitors
  • Myelin Proteins
  • Nerve Tissue Proteins
  • enhanced green fluorescent protein
  • monocyte-macrophage differentiation antigen
  • Green Fluorescent Proteins
  • Cuprizone